Thursday, analytical instruments provider Thermo Fisher Scientific Inc. (TMO) said it would acquire specialty in-vitro diagnostic tests provider B.R.A.H.M.S. AG for EUR 330 million, or about US$470 million. The transaction is expected to close in late September 2009 and is anticipated to be accretive to earnings per share in 2010.
Waltham, Massachusetts-based Thermo Fisher said that the deal is subject to applicable regulatory approvals and a customary post-closing purchase price adjustment.
Germany-based B.R.A.H.M.S. is owned jointly by its senior management team and a private equity firm, and is a provider of specialty in-vitro diagnostic tests based on patented biomarkers for sepsis, cardiovascular and pulmonary diseases, and also intensive care treatments and prenatal screening. B.R.A.H.M.S. also offers diagnostic tests and instrumentation for thyroid, prenatal, autoimmune and oncology screening in both laboratory and point-of-care settings.
According to the deal, B.R.A.H.M.S. will be integrated into the Specialty Diagnostics business within Thermo Fisher's Analytical Technologies Segment.
TMO closed Wednesday's regular trading at $43.28 per share on the New York Stock Exchange.
For comments and feedback: editorial@rttnews.com